3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
59
Myelodysplastic Syndromes
14
Leukemia
11
Recurrence
5
Leukemia, Promyelocytic, Acute
5
Congenital Abnormalities
5
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Erythroblastic, Acute
4
Anemia, Refractory, with Excess of Blasts
4
Leukemia, Megakaryoblastic, Acute
3
Neoplasm, Residual
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelomonocytic, Chronic
2
Sarcoma, Myeloid
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Disease Progression
1
Disease
1
Blast Crisis
1
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
Gemtuzumab
×
Clear all
NCT05904106
2024-12-02
VINCENT
Technische Universität Dresden
Phase 2
Recruiting
146 enrolled
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled